The 10-second takeaway
For the quarter ended June 30 (Q2), Actavis met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share grew significantly. GAAP loss per share grew.
Gross margins grew, operating margins dropped, net margins dropped.
Actavis reported revenue of $1.99 billion. The 15 analysts polled by S&P Capital IQ anticipated sales of $1.99 billion on the same basis. GAAP reported sales were 47% higher than the prior-year quarter's $1.36 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $2.01. The 19 earnings estimates compiled by S&P Capital IQ anticipated $2.00 per share. Non-GAAP EPS of $2.01 for Q2 were 42% higher than the prior-year quarter's $1.42 per share. GAAP EPS were -$4.27 for Q2 compared to -$0.49 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.2%, 280 basis points better than the prior-year quarter. Operating margin was 9.7%, 540 basis points worse than the prior-year quarter. Net margin was -28.4%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $2.05 billion. On the bottom line, the average EPS estimate is $2.11.
Next year's average estimate for revenue is $8.06 billion. The average EPS estimate is $8.32.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 230 members out of 251 rating the stock outperform, and 21 members rating it underperform. Among 94 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 90 give Actavis a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Actavis is outperform, with an average price target of $140.83.
- Add Actavis to My Watchlist.